Coherus Oncology, Inc. Increase (Decrease) in Other Operating Assets and Liabilities, Net
Coherus Oncology, Inc. (CHRS) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $42.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-08-05
- Coherus Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $38.87M, a 346.23% increase year-over-year.
- Coherus Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was $3.30M, a 79.90% increase year-over-year.
- Coherus Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was -$51.80M.
- Coherus Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was -$23.19M.
- Coherus Oncology, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was -$64.45M.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $38.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $42.17M 10-Q · filed 2026-08-05 | -$9.63M derived: sum of 3 quarters · filed 2026-08-05 | -$32.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.30M 10-Q · filed 2026-05-11 | -$48.50M derived: sum of 2 quarters · filed 2026-05-11 | -$71.69M derived: sum of 3 quarters · filed 2026-05-11 | -$62.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$51.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$74.99M derived: sum of 2 quarters · filed 2026-03-09 | -$66.28M derived: sum of 3 quarters · filed 2026-08-05 | -$64.45M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$23.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$14.48M derived: sum of 2 quarters · filed 2026-08-05 | -$12.64M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $8.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.55M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $1.84M 10-Q · filed 2026-05-11 | |||
| 2024-09-30 | -$7.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.82M derived: sum of 2 quarters · filed 2025-11-06 | -$2.40M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.78M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $1.42M 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |